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Introduction
Hepatitis B virus infection (HBV) remains a major public health challenge affecting well over 
400 million people worldwide [1,2]. Low and middle-income countries of Asia, Western pacific 
and sub-Saharan Africa bear the brunt of the disease with well over8% of their populations being 
hepatitis B surface antigen (HBsAg) positive [3]. 
In Cameroon like most sub Saharan Africa, regions of intense HBV infection coincide with 
areas of high prevalence of the Human immunodeficiency type one virus (HIV) thereby increasing 
the chances of dual HIV-HBV infections occurring. Within these region the majority of HBV 
infections occurs before 5 years of age through horizontal transmission from family members [4]. 
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Abstract
Pediatric vaccination against Hepatitis B Virus (HBV) leads to the induction of immunoglobulin G (IgG) 
antibodies specific to hepatitis B surface antigen (anti-HBs) consisting of four IgG subclasses. In the context of 
potential immuno-suppression arising from neonatal infection with the Immunodeficiency virus type one (HIV) 
an analyses of the anti-HBs response rate together with IgG subclass profiles especially in children vertically 
infected with HIV is of value in measuring the efficacy of childhood HBV vaccination. In this study we investigated 
in 50 HIV positive and 44 negative children the HBV vaccine response rate together with the profiles of IgG 
subclass responses specific to hepatitis B surface (HBsAg). The protective HBV vaccine response rate (anti-
HBs ≥10 mUI/ml) in the HIV infected children was 36% compared to 92 % in healthy controls. Whereas no 
difference was observed between the HIV positive and negative children with respect to IgM responses (P=0.99), 
a significant reduction in HBsAg specific IgG (P˂0.0001) and IgG subclass responses (P˂ 0.0001 for IgG1, 
P˂0.001 for IgG2, P<0.001 for IgG3 and P˂0.0001 for IgG4) was observed in HIV-1 infected children relative 
to their negative counterparts. Thus there is a significant reduction not only in the prevalence of sero-protective 
titer (anti-HBs ≥10mUI/ml) but equally in the IgG subclass responses specific to HBsAg amongst HIV-1 infected 
children. Both HIV positive and negative children showed minimal detectable levels of antibodies specific to the 
core protein (HBcAg) indicative low exposure to HBV. This was associated with elevated plasma levels of HBsAg 
specific IgG4 antibody responses probably indicating repeated exposure to the antigen. Our data highlights the 
necessity to monitor HBV vaccine responses in HIV infected children in Cameroon in order to revaccinate non-
immunized children.
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Childhood infection with HBV increases the likelihood of chronic 
HBV infection (with a rate >90%) in adulthood [5] together with 
persistent transmission of the virus. This is further compounded 
by concurrent HBV-HIV infection as it escalates the chronic HBV 
infection rate and also accelerates liver disease progression [6]. HBV 
infection of HIV positive individuals is also associated with increased 
HBV replication rates together with a longer than usual persistence 
of the HBV envelope antigen (HBeAg) thereby enhancing HBV 
transmission risk and pathology [6-8]. Since the combined effect of 
early childhood HBV and dual HIV-HBV infections significantly 
escalate disease progression mass immunization of newborn babies 
against HBV is strongly recommended irrespective of HIV infection.
Although the standard three dose HBV immunization schedules 
induces protective HBV specific immunity (HBsAg specific 
antibodies ≥10 mUI/ml) in well over 90% of immune competent 
children   a significantly lower sero conversion rate (25-41% in 
children) is reported in HIV infected children [9,10]. More so little 
is known about the HBV vaccine mediated IgG subclass responses in 
HIV infected individuals. There is evidence suggesting that increasing 
either the HBV vaccine dose or frequency in HIV infected children 
could improve vaccine mediated specific immunity [11,12]. However 
rather than recommending different vaccination schedules for HIV 
infected children the Current Centers for Disease Control and 
Prevention (CDC) guidelines suggest instead additional vaccine cycles 
for HIV-infected non-responder adults but not in children [13,14]. 
While these strategies could potentially increase HBV vaccine specific 
antibody titers in HIV infected individuals little is known about the 
profile of anti-HBs specific IgG subclass responses associated with 
the vaccination of HIV infected children. Never the less assessing 
anti-HBs IgG subclass responses following HBV vaccination of 
HIV infected children could provide critical information about the 
maturation and functions of the vaccine induced humoral immune 
responses.
Following natural seroconversion  IgG subclass responses 
specific to HBsAg have been demonstrated to be restricted mainly 
to neutralizing IgG1 and IgG3, with only a minor contribution from 
IgG2 and IgG4 [15,16]. The presence of both IgG1 and IgG3 is strongly 
associated with Th1 cytokines such as IL-2, IFN-γ and TNF-α which 
are critical in cell-mediated immunity and the induction of memory 
IgG responses [17]. Activation of Th1 response together with HBsAg 
specific IgG1 or IgG3 subclass responses is thus a critical necessity in 
the ultimate effective neutralization of HBV [18]. Unfortunately HIV 
infection in attacking and destroying CD4+ T cells probably leads 
to immune dysfunction and impairment of cellular and humoral 
responses in children which is vital in sustainable protective immunity 
[19]. Galina’s and colleagues showed a significant association between 
humoral immune response in 1 and 2 years old children and IFN-γ 
secretions [20]. These cytokines support the differentiation of CD4+ 
T cells to Th1 cells and suppresses the development of Th2 cells [21]. 
Th1 and Th2 cells activities are tightly linked to IgG subclass switch, 
which is an indicator of a sequential IgG subclass maturation and 
somatic hyper mutation of specific B cell clones [22,23]. 
Several studies in assessing humoral immune response to HBV 
vaccine in HIV infected individuals have focused on rate, quantity 
and duration [24-28]. However, there is limited data about the profiles 
of HBsAg specific IgG subclass responses of HIV-1 infected children 
following childhood HBV vaccination. Here we have assessed the 
profiles of HBsAg specific IgG subclass responses in HIV infected 
children following the completion of childhood HBV vaccination in 
Cameroon.
Methods and Participants
Study design and participants selection
This is a multicentric cross-sectional study conducted in five 
health centers of Cameroon namely, the Yaoundé University Teaching 
Hospital (CHUY), Efoulan District Hospital (EDH), Bikop Catholic 
Health center (CSCB), Social and Health Animation Center (CASS); 
and the Chantal Biya International Reference Centre for Research on 
the Prevention and Management of HIV/AIDS (CIRCB), Yaoundé. 
The University Teaching Hospital is a tertiary hospital in the capital 
city Yaoundé, receiving a wide variety of patients from all over 
Cameroon. The other selected health centers are   secondary   health 
facilities within and around Yaoundé, which provides health facilities 
to patients from rural and urban settings.
A total of 94 children aged 4 months to 5 years old were enrolled 
for this study. All together 44HIV-1 negative (control group) and50 
HIV-1 infected children born of antiretroviral therapy naïve HIV-1 
infected mothers were recruited for this study.
The study was conducted for a period of14 months and lasted from 
December 2014 to March 2016. The study participants were selected 
using consecutive sampling technique and written informed consent 
or assent was obtained from parents or legal guardians of the study 
participants (Children aged 4 months to 5 years who had completed 
the pediatric HBV vaccination as stipulated by the national program 
on immunization were considered eligible for the study. Pediatric 
HBV vaccination was confirmed through vaccination records. We 
excluded all children whose parents or legal guardians refused to 
give consent, those who provided incomplete data and those with 
incomplete pediatric HBV vaccination. We equally excluded children 
who were positive for prevalent endemic infections including HBV, 
HCV, Dengue virus infection and Malaria.
Sample collection
About three milliliters of peripheral blood was collected from 
each participant in Ethylene Diamine Tetra-Acetic Acid (EDTA)-
containing tubes. All samples were stored at room temperature and 
processed within 2 hours of collection. To obtain plasma, samples 
were centrifuged at 2,000 rpm for 10 min at 4°C. The plasma fraction 
was harvested under sterile conditions in a bio safety II hood, aliquot 
in small, single-use volumes and stored at -20°C until use. All plasma 
obtained from participants was heat inactivated for 30 minutes at 
56°C prior to ELISA assay. Prior to plasma separation and storage 
samples were tested for malaria, filarial, dengue, hepatitis B and 
hepatitis C virus infections. Blood collection was done at 4 weeks after 
the last HBV vaccine dose.
Sample analysis
Except for malaria and helper CD4+ T cell counts, plasma samples 
were used for all serological analysis. Malaria diagnosis was done 
using an SD BIOLINE®point of care kit (Giheung, Republic of Korea). 
SD BIOLINE® HBsAg and anti-HCV immuno chromatographic 
tests were used for the diagnosis of HBV and HCV, respectively. 
The CTK®OnSite (San Diego, USA) Duo Dengue Ag-IgG/IgM rapid 
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test was used for the simultaneous detection and differentiation of 
DENV specific IgM and IgG antibodies as well as NS1 antigen for 
all the samples. Absolute numbers of helper CD4+ T cells for HIV-
1+ participants were determined in fresh whole blood by BD multi 
test CD3/CD8/CD45/CD4 and TruCount tubes (BD Biosciences, San 
Jose, USA) according to the manufacturer’s instructions.
Laboratory analysis for the detection of plasma levels of 
HBsAg specific antibodies
Quantification of Anti-HBs in participants’ plasma was 
done using abioelisa anti-HBs Kit (Biokit S.A, Barcellona, Spain) 
according to the manufacturer’s instructions. Briefly100ul/well of 
each participant’s Plasma was added into an ELISA plate pre-coated 
with highly purified HBsAg. After which plates were incubated 
at 37˚C for one hour before washing for 4 times with wash buffer 
provided with the kit. Next 100 ul/well of HBsAg conjugated to Horse 
Radish Peroxidase (HRP) is added and incubated at 37˚C for 30 
minutes. Following a 4x wash, 100ul/well of substrate is then added 
and incubated at room temperature for 30 minutes. The reaction 
is stopped with 100 ul/well of sulphuric (stop solution) and the 
OD determine at 450 nm. The concentration of anti-HBs for each 
participant was calculated from a standard curve generated according 
to the manufacturer’s instructions. Anti-HBs concentration in this 
study were categorized as i) no response, ii) < 10 mIU/ml and iii) > 10 
mIU/ml. The protective anti-HBs concentration was taken to be equal 
or greater than 10 mIU/ml. 
Quantitative determination of anti-HBs and anti-HBc 
antibodies
Plasma samples were analyzed for HBsAg and HBcAg specific 
antibody responses using an optimized in-house ELISA protocol 
previously described [29]. Briefly 96-wells flat-bottomed high 
binding Costar® assay plates (CORNING, USA) were coated either 
with recombinant HBsAg or HBcAg (IMMUNODX Woburn, MA, 
USA) dissolved in PBS (50 ng/well) and incubated at 4°C overnight. 
The following day, plates were washed three times with PBST (PBS 
with 0.05 % Tween-20) and blocked either with 3% BSA or 1x Roti 
block (Carl ROTH, Karlsruhe, Germany) for one hour at 37°C. After 
an additional washing step, 100 µl/well of plasma diluted (1:500) in 
PBS was added into corresponding wells in triplicates and incubated 
for two hours at 37°C. 
Next the plates are washed five times as described above. Then 
100µl horseradish peroxidase (HRP)-conjugated anti-human IgG 
(1:2000) and Horseradish Peroxidase (HRP)-conjugated anti-human 
IgG1, IgG2, IgG3, IgG4, or IgM (1:4000) antibodies were added, and 
the plates incubated for 1h at 37°C. Antibody isotypes and subclasses 
used in this study were mouse anti-human IgG Fc (clone JDC-10), 
mouse anti-human IgM (clone UHB), mouse anti-human IgG1 Fc 
(clone HP6001), mouse anti-human IgG2 Fc (clone 31-7-4), mouse 
anti-human IgG3 Hinge (clone HP6050) and mouse anti-human IgG4 
pFc’ (clone HP6023), all HRP conjugated antibodies were procured 
from Southern Biotech® (Birmingham, USA). Plates were then 
washed five times and 100µl of 2,2′-Azino-bis (3-ethylbenzthiazoline-
6-sulfonic acid) or ABTS one Component HRP substrate was added 
to each well and incubated in the dark for 30 min. The enzyme 
substrate reaction was stopped by adding a stop solution (Southern 
Biotech, Birmingham, USA). The Optical Densities (OD) at 405nm 
were read using a multiscan Fc Elisa microplate reader (Thermo-
scientific, USA). All plasma was tested in triplicate and the mean OD 
values were determined after normalization with background values 
derived from wells treated with validated anti-HBs plasma samples 
similarly treated.
Ethical approval
This study was approved by the Cameroon National Ethical 
Committee under protocol number 2014/07/474/CE/CNERSH/
SP. All parents or legal guardians gave a written informed consent. 
Children that tested positive for any of prevalent endemic diseases 
were excluded from the study and recommended to qualified 
pediatrician for clinical follow up.
Statistical analysis
Continuous variables from children’s characteristics and antibody 
response profiles were described as medians and Inter Quartile 
Ranges (IQR) and categorical variables were presented as percentages 
or proportions. Comparison between groups were made using the 
non-parametric Mann-Whitney U test for continuous variables and 
Chi square or Fischer exact tests were used for categorical variables 
as appropriate. The level of statistical significance was set at p < 0.05. 
Statistical analysis was performed using Graph Pad Prism version 6.0 
software.
Results
Study Population Characteristics
The study included 50 HIV-1 positive children vertically infected 
with HIV by women who did not participate in the national PMTCT 
program. A total 26 females with median age 30 months (IQR 20-
49) and 24 males with a median age of 48 months (IQR 34-59) were 
recruited. The median (IQR) CD4+ cells count among male and 
female children were 1583 (1021-2188) and 1963 (1053-2124) cells/
mm3 respectively. Amongst the HIV infected children 42 (20 male 
and 22 female) out of the 50 children were under antiretroviral 
therapy during this study, and 8 (16%) were ART naïve. As controls44 
HIV negative children consisting of 21 females with  a median age of 
10 months (IQR, 6-23) and 23 males with a median age of 10 months 
(IQR 6-19) were also recruited. All participants completed the HBV 
vaccination schedule were both HBsAg and HBV envelope antigen 
(HBeAg) negative.
Comparative analysis of the concentration of anti-HBs and 
the HBV vaccine response rate between HIV positive and 
negative children
Four weeks following the last HBV vaccine dosethe protectiveanti-
HBs seroconversion (anti-HBs ≥10 mUI/ml) rate was 36 % in the 
HIV+ compared with 96 % in their negative counterparts (Figure 
1A). When anti-HBs concentrations were categorized as i) no 
response, ii) < 10 mIU/ml and iii) > m10 IU/ml; significantly higher 
frequencies of HIV infected children were either non-responders or 
had non-protective levels of ant-HBs. With respect to IgM antibody 
responses HIV+ positive children showed HBsAg specific IgM 
antibody responses (P=0.99) comparable to seronegative children. 
On the other hand, HBsAg specific IgG responses were significantly 
(P<0.0001) reduced in HIV infected children relative to the health 
controls (Figure 1B).
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HBs Ag specific IgG subclass antibody responses in HIV 
infected children
HBsAg specific IgG subclass responses including IgG1 (P<0.0001), 
IgG2 (0.0001), IgG3 (P<0.001) and IgG4 (P<0.0001) responses 
specific to HBsAg were significantly higher in HIV negative children 
than their positive counter parts (Figure 1B and 1C). The pattern of 
hepatitis B surface antigen specific IgG antibody subclass responses 
in HIV-1 negative children was IgG3=IgG1=IgG4>IgG2 compared to 
the HIV positive children which was IgG3>IgG4=IgG1>IgG2. 
Hepatitis B surface antigen specific IgM and IgG antibody 
responses amongst HIV-1 infected ARV therapy naive and 
treated children
Antiretroviral treated HIV-1 infected children showed similar 
HBsAg specific IgM and IgG antibody response like Antiretroviral 
Therapy (ART)  naïve participants (P=0.99) (Figure 3A). However 
when HBsAg specific IgG subclass responses were considered apart 
from the IgG3 subclass responses in ART treated children which was 
significantly higher (P=0.0035) than ART naïve children, all other 
HBsAg specific IgG subclass responses including IgG2 (P=0.99), 
IgG1 (P=0.137) and Ig4 (p=0.449) were similar between the two 
groups (Figure 3B). Thus the overall effect of ART was a significant 
improvement in HBsAg specific IgG3 subclass responses.
HBsAg specific antibody response profiles according to 
age of the vaccinated children
We next categorize the participants into three main age groups 
consisting of 4 to 12, 13 to 24 and 25 to 60 months old respectively. 
The overall HBsAg specific IgM antibodies responses were similar 
between the different age groups in both HIV infected and negative 
(Figure. 4A). In contrast for all three age groups IgG antibody 
responses were significantly higher in the HIV negative than HIV 
positive children. The same trend was also observed with IgG1, IgG2 
and IgG4 subclass responses (Figure 4B, C, D & F). On the other 
hand no difference is observed between the HIV positive and negative 
children with respect to HBsAg specific IgG3 subclass responses 
(Figure 4E). 
Hepatitis B core antigen (HBc) specific IgM and IgG 
antibody responses in HIV infected children
Less than 10% of both HIV positive and negative children 
showed antibodies specific to the core antigen. Where HIV infected 
children showed similar HBcAg specific IgM responses (P=0.99) 
like the negative children (Figure 5A), HBcAg specific IgG antibody 
responses were significantly higher in the negative children 
(P=0.0001). The majority of the children had as consequence also 
extremely low prevalence of HBcAg specific IgG subclasses responses 
(compare Figure 5 B, C, D& E). HBc A specific IgG subclass responses 
were similarly between HIV negative and positive children thereby 
suggestion low infection with HBV (Table 1).
Figure 3: Effect of ART on HBsAg specific antibody response in HIV infected 
children. In (A) data for HBsAg specific IgM and IgG antibody responses 
are shown whilst (B) represents the profile of HBsAg specific IgG subclass 
responses in both ART treated and therapy naïve HIV infected children. P: 
p-value at 0.05 significant level.
Figure 2: Hepatitis B surface antigen specific IgG subclass responses in 
HIV negative and positive children after childhood vaccination against HBV 
infection.
In (A) comparison between HIV negative and positive children on their HBsAg 
specific IgG1 and IgG3 subclass responses. (B) is a similar comparison but 
this time around for HBsAg specific IgG2 and IgG4 subclass responses. In 
(C) the profile of hepatitis B surface antigen specific IgG subclass responses 
is shown for HIV negative children whilst (D) shows similar data for the 
positive children. P: p-value at 0.05 significant levels.
Figure 1: Hepatitis B surface antigen specific antibody responses in HIV 
negative and positive children after childhood vaccination against HBV 
infection.
In (A) proportion of anti-HBs responders in the study population. In (B) 
HBsAg specific IgM and IgG isotype responses. In (C) a correlation between 
CD4+/CD8+ ratio and HBsAg specific IgM antibody response whilst (D) is a 
correlation between CD4+/CD8+ ratio and anti-HBs IgG response.  p-value 
at 0.05 significant level.
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Discussion
In this study we have assessed the rate, concentration and IgG 
antibody subclass responses specific to HBV vaccine in 50 HIV 
infected as well as 44 HIV negative children one month after the last 
pediatric HBV vaccine dose. A direct consequence of HIV infection 
was a significant reduction in the rate, concentration and the profile 
of IgG subclass responses. The sero-protective HBV vaccine response 
rate (anti-HBs ≥10 UI/ml) in the HIV infected children was 36% 
compared to 92 % in healthy controls. The protective response rate 
to HBV vaccine as reported in terms of a seroconversion with anti-
HBs antibodies > 10UI/mL is usually in the range of 90 to 95%39. 
However in HIV infected individuals the induction of sero-protective 
levels of anti-HBs antibodies as a consequence of HIV driven 
immune-depletion is severely impaired. The greater majority of the 
children (>60 % for HIV positive versus <10% for negative children) 
had serum anti-HBs IgG levels less than 10 IU/l. In this study the 
induction anti-HBs antibody following Child Hood vaccination 
against HBV as previously reported30-34 was severely impaired in 
children vertically infected with HIV.
Given the above HBV vaccine response rate and low levels of 
HBsAg specific IgG antibodies the need arises to regularly monitor 
anti-HBs following the last HBV vaccine dose in HIV infected 
children to identify non-immunized individuals for revaccination. 
There is also a need for sustained monitoring of HIV infected 
children to long understand the impact of poor vaccine responses 
on the emergence of HBV related diseases and cancers. In addition 
despite comparatively similar levels of IgM specific to HBsAg in both 
HIV positive and negative children levels of IgG antibodies were also 
significantly reduced (P=0.0001) in the HIV infected children (Fig 
1B). This was mirrored in the profile of HBsAg specific IgG subclass 
responses including IgG1 (P=0.0001), IgG2 (p=0.0001), IgG3 
(P=0.0001) and IgG4 (P=0.0001) which were all significantly lower in 
the HIV infected children [33] (Figure 2 A&B). 
Since IgM responses were similar between the two groups 
the differences observed in HBsAg specific IgG and IgG subclass 
responses is probably as a result of an impaired ability of HIV infected 
children to generate adequate IgG antibody responses to HBV vaccine 
[34]. This is probably because the IgG subclass content is dependent 
upon the functions of the germinal center which is responsible 
for the functional diversification of IgG antibody responses and 
the generation of class switched long lasting memory B cells [35]. 
Figure 4: Hepatitis B surface antigen specific antibody responses in both 
HIV negative and positive children according to age.
In (A) IgM antibody, (B) IgG antibody, (C) IgG1 antibody, (D)  IgG2 antibody, 
(E) IgG3 antibody  and (F) IgG4 antibody responses. P: p-value at 0.05 
significant level.
Figure 5: Proportion ofHBcAg specific antibody subclass response rates in 
HIV negative and HIV infected children.
In (A) comparative analysis of HBcAg specific IgM and IgG responses 
is shown for both HIV positive and negative children. In (B) proportion 
based on HBcAg specific IgG1 subclass response; (C) proportion based 
on HBcAg specific IgG2 subclass; (D) proportion based on HBcAg specific 
IgG3 subclass and (E) proportion based on HBcAg specific IgG4 subclass 
responses.
Table 1: Study population characteristics.
n: Number; IQR: Inter Quartile Range; ART: Antiretroviral Therapy; **:P<0.001; ****:P<0.0001; (a): Mann-Whitney test comparing median age of a given gender 
between groups.
Variable HIV- (n=44) HIV+ (n=50)
Gender Male Female Male Female
Participants n (%) 23 (52.27) 21 (47.73) 24 (48) 26 (52)
Median age (IQR)in months(a) 10(6-19) 10 (6-23) 48(34-59) **** 30 (20-49) **
HIV status Negative Negative Positive Positive
CD4+(IQR), in Cells/mm3 N/A N/A 1583 (1021 -2188) 1963 (1053-2124)
ART n (%) N/A N/A 20 (83.33) 22 (84.61)
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The induction of IgG subclass responses which is a critical step in 
memory B cell generation also occurs in the light zone of the germinal 
center where their B cells (centrocytes) would undergo class switch 
recombination [36]. In this zone interactions between follicular helper 
CD4+ T cells, follicular dendritic cells and primed B cells determine 
the IgG subclass content and the durability of memory B cells35.
HIV have been reported to infect cells of the germinal center such as 
follicular helper T cells leading to severe immune dysfunction. In this 
light impaired vaccine mediated humoral immune responses in HIV 
infected people have been linked to the loss of memory B cells during 
disease progression [37-39]. This probably suggests that HBV vaccine 
specific immune response development in HIV infected children 
might also be impaired with respect to IgG subclass generation (class 
switch). This implies that HBsAg specific IgM antibody responses 
might be the main antibody isotype responsible for HBV vaccine 
immunity in HIV infected individuals.
In both groups HBsAg specific IgG subclass antibodies were 
mainly restricted to IgG1, IgG3 and IgG4 subclasses. The IgG2 level 
of anti-HBs was the lowest IgG subclass for both groups (Figure 2 
C&D). Whereas levels of HBsAg specific IgG1 and IgG3 were similar 
in the vaccinated HIV negative children these subclasses of anti-HBs 
in the HIV infected children was dominated by IgG3 with IgG1 being 
severely diminished. This suggests that in contrast to healthy controls 
IgG3could be the main anti-HBs IgG subclass following pediatric 
vaccination of HIV infected children against HBV.
The implementation of mass immunization programs, which 
have been recommended by the World Health Organization since 
1991, have dramatically decreased the  incidence of HBV  infection 
among  infants, children,  and  adolescents  in  many  countries40.
It is known that, immune responses to most vaccine are impaired in 
individuals infected with HIV [41,42]. Our data suggest that HBsAg 
vaccine specific-humoral immune response maturation might also 
be impaired in HIV-1 infected children. Successful vaccination using 
recombinant HBV vaccine is a T-cell-dependent process [43] and the 
reduction in HBV vaccine mediated antibody responses among HIV-
infected children might be a consequence HIV driven deregulation of 
the functions of the germinal center [44] where helper CD4+ T cells 
are known to provide critical help during the maturation of antibody 
responses. Since there is a direct correlation between HBV directed 
humoral and cell mediated immunity20 such a dysfunction of the 
germinal center might lead to a decrease in HBsAg specific IgG1, 
IgG2, IgG3 and IgG4 due to a limitation in class-switching after HBV 
vaccination of HIV-1 infected children.
Moreover, ongoing HIV replication is associated with B cell 
deregulations, increased B cell activation and turnover, and an 
increase in immature and transitional B cells [45,46]. This results in 
the loss of memory B cells and the decrease in levels of previously 
induced antibody [37,38,45,47]. HIV-1 Nef has also been shown to 
directly perturb B-cell class switching [48-51]. In fact, Nef suppresses 
CD40-dependent immunoglobulin class switching in bystander B 
cells [52].
In this study IgG4 response was unusually elevated amongst the 
IgG subclass antibody responses in both HIV infected and negative 
children. This is probably due to the fact that IgG4 is associated with 
chronically exposed antigens and thus might be involved in immune 
response down-regulation or tolerance induction function [53]. 
Treatment of HIV-1 infected children with antiretroviral drugs 
therapy improved both anti-HBs and anti-HBc specific antibody 
responses. In antiretroviral therapy naive HIV-1 infected children 
there was a significant reduction in HBsAg specific IgG3 responses 
relative to their ART treated counterparts.  Similarly HBcAg specific 
IgM, IgG and IgG4 were also significantly lower in ART therapy 
naive HIV-1 infected children relative to those ART treated. ART 
therapy is known to suppress HIV-1 replication and the reduction 
of pro-inflammatory cytokines in lymphoid tissue [54], leading to 
an improvement in immune responses [55]. Improved HBV vaccine 
specific antibody responses in ART treated children is an indication 
of partial immune restoration following treatment of HIV infected 
children.
Our study had some limitations, one of which being that only 
plasma was analyzed for HBV vaccine specific immune responses. 
This might not be sufficient to decipher all the problems related to 
poor HBV vaccine responses in HIV infected children. Secondly the 
relatively small sample size of the study population might not be a 
true representation of the entire population of HIV infected children 
in Cameroon. Never the less our study assessed the humoral response 
to HBV vaccine as well as possible exposure to HBV infection during 
early infancy. 
Conclusion
We have shown that anti-HBs immune response rate, 
concentration and HBsAg specific IgG subclass antibody responses 
are impaired in HIV infected children.  Thus the HIV infected 
children’sHBV vaccine immune responses might not be as effective 
as that of their negative counterpart for reasons that include lack 
of immunologic memory, immaturity and low level HBsAg specific 
IgG subclass antibody responses. Given that anti-HBs titer is a 
strong correlate for predicting protection after HBV vaccination; 
HIV infected children should be tested regularly for anti-HBs 
concentration in order to give booster injection when titers are below 
10mIU/ml. There is also need for long-term monitoring to establish 
the absence of clinically significant breakthrough instances of HBV 
infections.
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